Drug Profile
Rosuvastatin - Hanmi Pharmaceuticals
Alternative Names: HGP 0816Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-III for Dyslipidaemias (Combination therapy) in South Korea (PO)
- 29 Jan 2019 Chemical structure information added
- 01 Oct 2016 Hanmi Pharmaceuticals completes phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)